Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.
Dinneen E, Shaw GL, Kealy R, Alexandris P, Finnegan K, Chu K, Haidar N, Santos-Vidal S, Kudahetti S, Moore CM, Grey ADR, Berney DM, Sahdev A, Cathcart PJ, Oliver RTD, Rajan P, Cuzick J; PROVENT study group; Cuzick J, Madaan S, Pati J, Chowdhury AM, Birch BRP, Dudderidge TJ, Moore CM, Grey ADR, Shaw GL, Jefferson KP, Kynaston HG, Rajan P, Green JSA, Cathcart PJ, Berney DM, Powles T, Oliver RTD, Sahdev A, Kealy R, Kemp V, Alexandris P, Finnegan K, Chu K.
Dinneen E, et al. Among authors: oliver rtd.
BJUI Compass. 2022 Jun 11;3(6):458-465. doi: 10.1002/bco2.169. eCollection 2022 Nov.
BJUI Compass. 2022.
PMID: 36267207
Free PMC article.